FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2386249122> ?p ?o ?g. }

• W2386249122 endingPage "122" @default.
• W2386249122 startingPage "122" @default.
• W2386249122 abstract "Purpose: The incidence rate and the mortality rate of gastric cancer have decreased in developed countries over the last several decades. On the other hand, they remain high in far eastern countries such as Korea, Japan, China and in many developing countries. The cure of patients with gastric carcinomas can be achieved mostly through complete surgical resection, but most gastric cancer patients are in advanced stages when diagnosed and have poor prognoses. therefore, the development of an effective systemic therapy is essential for far advanced gastric cancer patients. Until recently, the most commonly used combination chemotherapy was based on 5-flurouracil or cisplatin, but the results were not satisfactory, so recently etoposide, adriamycin and cisplatin (EAP-II) combination chemotherapy was introduced in patients with advanced gastric cancer. Early studies showed a high response rate and the ability to convert unresectable cases to resectable ones, but later studies couldn't duplicate the result. the purpose of this study was to evaluate the relative efficacy & toxicity of EAP-II chemotherapy and ELF chemotherapy which is based on 5-flurouracil. Materials and Methods: Between July 1992 and July 2002, sixty-five patients with inoperable advanced gastric cancer were enrolled for this study. Thirty-seven patient received EAP-II chemotherapy:etoposide (20 mg/ IV for ), adriamycin (20 mg/ IV for ) and cisplatin (20 mg/ IV for ) and Twenty-eight patients receieved ELF chemotherapy : etoposide (100 mg/ IV for ), leucovorin (20 mg/ IV for ) and 5-FU (500 mg/ IV for ). Each treatment schedule for each group was repeated every four weeks: EAP-II means 3.4 cycles per patient..ELF means 4.1 cycles per patient Results: Total respones rates were in the ELF group and in the EAP group (P-value>0.05). The median times to progression were 144 days in the ELF group and 92 days in the EAP-II group (P-value0.05). The difference in the survival curves for the two regimens was not statistically significant. Non-hematologic toxicitis & hematologic toxicitis were more frequently observed for the EAP-II regimen. Anemia: in ELF vs in EAP-II; Leukopenia: in ELF vs in EAP-II; nausea & vomiting: in ELF vs in EAP-II. Conclusion: EAP-II regimen is not superior to ELF regimen in the tratment of inoperable advanced gastric cancer" @default.
• W2386249122 created "2016-06-24" @default.
• W2386249122 creator A5010391034 @default.
• W2386249122 creator A5021059398 @default.
• W2386249122 creator A5027841724 @default.
• W2386249122 creator A5046721554 @default.
• W2386249122 creator A5049274840 @default.
• W2386249122 creator A5053217175 @default.
• W2386249122 creator A5061383776 @default.
• W2386249122 creator A5075537261 @default.
• W2386249122 creator A5080920509 @default.
• W2386249122 creator A5083501367 @default.
• W2386249122 creator A5087451889 @default.
• W2386249122 creator A5091420108 @default.
• W2386249122 date "2003-01-01" @default.
• W2386249122 modified "2023-10-18" @default.
• W2386249122 title "Retrospective Study on the Therapeutic Effects of an Etoposide, Adriamycin, Cisplatin-II (EAP- II) versus an Etoposide, Leucovorin, 5-Furorouracil (ELF) Combination Chemotheraphy in Unresectable Gastric Cancer" @default.
• W2386249122 doi "https://doi.org/10.5230/jkgca.2003.3.3.122" @default.
• W2386249122 hasPublicationYear "2003" @default.
• W2386249122 type Work @default.
• W2386249122 sameAs 2386249122 @default.
• W2386249122 citedByCount "1" @default.
• W2386249122 crossrefType "journal-article" @default.
• W2386249122 hasAuthorship W2386249122A5010391034 @default.
• W2386249122 hasAuthorship W2386249122A5021059398 @default.
• W2386249122 hasAuthorship W2386249122A5027841724 @default.
• W2386249122 hasAuthorship W2386249122A5046721554 @default.
• W2386249122 hasAuthorship W2386249122A5049274840 @default.
• W2386249122 hasAuthorship W2386249122A5053217175 @default.
• W2386249122 hasAuthorship W2386249122A5061383776 @default.
• W2386249122 hasAuthorship W2386249122A5075537261 @default.
• W2386249122 hasAuthorship W2386249122A5080920509 @default.
• W2386249122 hasAuthorship W2386249122A5083501367 @default.
• W2386249122 hasAuthorship W2386249122A5087451889 @default.
• W2386249122 hasAuthorship W2386249122A5091420108 @default.
• W2386249122 hasConcept C121608353 @default.
• W2386249122 hasConcept C126322002 @default.
• W2386249122 hasConcept C143998085 @default.
• W2386249122 hasConcept C2776694085 @default.
• W2386249122 hasConcept C2778119113 @default.
• W2386249122 hasConcept C2778239845 @default.
• W2386249122 hasConcept C71924100 @default.
• W2386249122 hasConceptScore W2386249122C121608353 @default.
• W2386249122 hasConceptScore W2386249122C126322002 @default.
• W2386249122 hasConceptScore W2386249122C143998085 @default.
• W2386249122 hasConceptScore W2386249122C2776694085 @default.
• W2386249122 hasConceptScore W2386249122C2778119113 @default.
• W2386249122 hasConceptScore W2386249122C2778239845 @default.
• W2386249122 hasConceptScore W2386249122C71924100 @default.
• W2386249122 hasIssue "3" @default.
• W2386249122 hasLocation W23862491221 @default.
• W2386249122 hasOpenAccess W2386249122 @default.
• W2386249122 hasPrimaryLocation W23862491221 @default.
• W2386249122 hasRelatedWork W1994063111 @default.
• W2386249122 hasRelatedWork W2061876674 @default.
• W2386249122 hasRelatedWork W2077334567 @default.
• W2386249122 hasRelatedWork W2197997348 @default.
• W2386249122 hasRelatedWork W4205099597 @default.
• W2386249122 hasRelatedWork W4237537544 @default.
• W2386249122 hasRelatedWork W4239046464 @default.
• W2386249122 hasRelatedWork W4246288932 @default.
• W2386249122 hasRelatedWork W4246355098 @default.
• W2386249122 hasRelatedWork W4250690813 @default.
• W2386249122 hasVolume "3" @default.
• W2386249122 isParatext "false" @default.
• W2386249122 isRetracted "false" @default.
• W2386249122 magId "2386249122" @default.
• W2386249122 workType "article" @default.